About Alteogen
Alteogen is a publicly listed company based in Daejeon (South Korea) founded in 2008. Antibody and protein biosimilars for cancer and disorders are developed. Its website alteogen.com draws about 58 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
Alteogen is a biosimilar company focussed on developing the monoclonal antibody (mAb) and protein-based biosimilars for the range of diseases. It is using 2 proprietary technologies to develop its pipeline. Based on the NexP fusion technology, it is fusing therapeutic proteins with the NexP protein carrier derived from A1AT (alpha-1 antitrypsin) so as to protect its activity. There are 5 candidates based on this technology with the lead candidate hGH-NexP in phase 1 trials. The other technology NexMab makes the anti-cancer chemical drugs to conjugate to the C-terminus of antibody protein site-specifically and is currently developing Trastuzumab-drug conjugate and Q5-drug conjugate for breast and ovarian cancer respectively.
- Headquarters Daejeon, South Korea
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website alteogen.com
- Social LinkedIn
- Legal Name Alteogen Inc.
- Annual Revenue$149.47 M (USD)109.87as on Dec 31, 2025
- Net Profit$98.1 M (USD)127.57as on Dec 31, 2025
- EBITDA$77.82 M (USD)297.78as on Dec 31, 2025
IPO & Listings of Alteogen
Alteogen is a publicly listed company on the KRX with ticker symbol 196170 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Dec 2014
- Listed onKRX: 196170
- Listed entityALTEOGEN Inc.
- Exchange sectorHealth technology
- ISINKR7196170005
- Share price224,500.00 KRW · 2026-10-14
- Market capitalisation15,632,254,676,819.00 KRW
- Price to earnings92.6
- EPS (diluted, trailing year)2,423.92 KRW
- Dividend yield0.13%
- Volume (last session)255,782
Financials of Alteogen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 215.86B KRW | 141.67B KRW | 112.39B KRW |
| 2024 | 102.85B KRW | 62.25B KRW | 28.25B KRW |
| 2023 | 96.52B KRW | -3.37B KRW | -6.40B KRW |
| 2022 | 28.81B KRW | -8.15B KRW | -26.72B KRW |
| 2021 | 38.75B KRW | -6.27B KRW | -13.04B KRW |
Detailed financial statements for Alteogen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Alteogen
The website of Alteogen (alteogen.com) receives about 58.3K visits a month and ranks #679,971 among all websites worldwide, #758 in Biotechnology and Pharmaceuticals.
- Monthly visits58.3K
▲ 56.6% vs previous month
- Unique visitors19.9K
per month
- Global rank#679,971
among all websites
- Category rank#758
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit3.0
- Average visit1 min 09 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Alteogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cphi-online.com | 100% | #227,074 | View details | ||
| hitnews.co.kr | 72% | #146,502 | View details | ||
| medisobizanews.com | 60% | #283,693 | View details | ||
dailypharm.com | dailypharm.com | 60% | #33,384 | – | |
medipana.com | medipana.com | 60% | #266,587 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Alteogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alteogen
Complete news archive for Alteogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alteogen
Alteogen was founded in 2008.
Alteogen is headquartered in Daejeon, South Korea.
Annual revenue of Alteogen is $149.47M as on Dec 31, 2025.
Alteogen is a biosimilar company focussed on developing the monoclonal antibody (mAb) and protein-based biosimilars for the range of diseases. It is using 2 proprietary technologies to develop its pipeline. Based on the NexP fusion technology, it is fusing therapeutic proteins with the NexP protein carrier derived from A1AT (alpha-1 antitrypsin) so as to protect its activity. There are 5 candidates based on this technology with the lead candidate hGH-NexP in phase 1 trials. The other technology NexMab makes the anti-cancer chemical drugs to conjugate to the C-terminus of antibody protein site-specifically and is currently developing Trastuzumab-drug conjugate and Q5-drug conjugate for breast and ovarian cancer respectively.
Yes, Alteogen is publicly traded on KRX under the ticker symbol 196170.